Mads Engell Refstrup Sørensen

Mads Engell Refstrup Sørensen

Auto-generated profile, based on publicly available information

Mads Engell Refstrup Sørensen

Center of Rheumatic Research Aalborg (CERRA), Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2024 in Rheumatology International
Verified
Journal Article
Open access
PDF file
LULine Uhrenholt
Line Uhrenholt
MSMads E. R. Sørensen
Mads E. R. Sørensen
KLKaren B. Lauridsen
Karen B. Lauridsen
KDKirsten Duch
Kirsten Duch
LDLene Dreyer
Lene Dreyer
SKSalome Kristensen
Salome Kristensen
To evaluate tumour necrosis factor inhibitor (TNFi) drug-levels and presence of anti-drug antibodies (ADAb) in patients with inflammatory arthritis who taper TNFi compared to TNFi continuation. Patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis on stable TNFi dose and in low disease activity ≥ 12 months were randomised (2:1) to disease activity-guided tapering or control. Blood samples at baseline, 12- and 18-months were evaluated for TNFi drug-levels and ADAb. In total, 129 patients were randomised to tapering (n = 88) or control (n = 41). Between baseline and month 18, a significant shift in TNFi drug-levels were observed in the tapering group resulting in fewer patients with high drug-levels (change: − 14% [95% CI − 27 to − 1%]) and more with low drug-levels (change: 18% [95% CI 5–31%]). Disease activity was equivalent between groups at 18 months, mean difference: RA − 0.06 (95% CI − 0.44 to 0.33), PsA 0.03 (95% CI − 0.36 to 0.42), and axSpA 0.16 (− 0.17 to 0.49), equivalence margins ± 0.5 disease activity points. ADAb were detected in eight patients, all from the tapering group. TNFi drug-level category or ADAb were not predictive for achieving successful tapering at 18 months. TNFi drug-levels decreased during tapering which indicate adherence to the tapering algorithm. Despite the difference in TNFi drug-levels at 18 months, disease activity remained equivalent, and only few tapering patients had detectable ADAb. These data do not support using TNFi drug-level and/or ADAb to guide the tapering decision but future research with larger trials is needed.Trial registration: EudraCT: 2017-001970-41, December 21, 2017.

8 August 2025 in EULAR Rheumatology Open
Verified
Journal Article
Open access
LULine Uhrenholt
Line Uhrenholt
MSMads Engell Refstrup Sørensen
Mads Engell Refstrup Sørensen
JSJan Sørensen
Jan Sørensen
AOAnne Estrup Olesen
Anne Estrup Olesen
RCRobin Christensen
Robin Christensen
SKSalome Kristensen
Salome Kristensen
We assessed the cost-effectiveness of disease activity–guided tapering to continuation of biologics as usual care in inflammatory arthritis. Adults with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis on stable biological dose (including biosimilars) and in low disease activity ≥12 months were randomised (2:1) to disease activity–guided tapering or continuation of biologics as usual care. The cost-effectiveness evaluation assessed the 18-month quality-adjusted life years (QALYs), hospital costs, and patient costs. Analyses were based on intention-to-treat. Missing short form six-dimensional (SF-6D) values were imputed with the mean SF-6D value in the relevant group at the specific time point. Patients lost to follow-up were assumed to continue their baseline biological dose onwards. We used a 2-sample t tests with unequal variance to capture between-groups differences with 95% CI. Of 142 included patients, 78% were treated with biosimilars. At 18 months, 75% (71/95) of the tapering group and 17% (8/47) of the control group were on a tapered biological dose. We found no difference between groups in QALYs, mean difference: 0.008 points (95% CI: −0.008 to 0.024). Patients in the tapering group incurred significantly lower mean hospital costs than the control group, between-group difference: −1936€ (95% CI: −3753€ to −119€). Mean patient costs were comparable between groups: −52€ (95% CI: −350€ to 246€). Disease activity–guided tapering of biologics in a biosimilar era resulted in substantial reductions in 18-month hospital costs, whereas the impact on QALY and patient costs was similar. Thus, the tapering algorithm was cost-saving.

29 October 2025 in Rheumatology
Verified
Journal Article
Closed access
MSMads E R Sørensen
Mads E R Sørensen
RCRené Cordtz
René Cordtz
KDKirsten Duch
Kirsten Duch
MSMaria Stilling-Vinther
Maria Stilling-Vinther
LDLene Dreyer
Lene Dreyer
SKSalome Kristensen
Salome Kristensen
Objectives: This study aimed to assess the risk of hospitalization with pneumonia (HP) among patients with GCA and ANCA associated vasculitis (AAV). Methods: This population-based cohort study identified patients with GCA and AAV diagnosed between 2000 and 2021 using the Danish National Patient Registry. Patients were matched 1:10 with controls on sex and year of birth. Using the pseudo-observation method we evaluated the cumulative incidence proportion (CIP) and risk difference (RD) after one, two and five years. Furthermore, a nested-case control (NCC) analysis was carried out to assess variables affecting the risk of HP. Results: The CIP of HP for 9307 patients with GCA was 6.0% (5.5–6.5), 9.4% (8.8–10.0) and 17.6% (16.8–18.4) after one, two and five years. The RD compared with 92 806 matched controls was 3.0% (2.6–3.5), 3.8% (3.2–4.4), to 5.3% (4.5–6.1). For 2401 patients with AAV, the CIP of HP was 12.6% (11.2–13.9), 17.9% (16.3–19.5) and 28.3% (26.4–30.3) after one, two and five years. Compared with 24 013 matched controls, the RD was 10.1% (8.8–11.5), 14.8% (12.3–15.4) and 20.4% (17.9–21.8). The NCC found comorbidities and immunosuppressive treatment to be associated with higher risk of HP. Conclusion: Patients with GCA or AAV had increased risk of HP compared with matched controls. Comorbidities and recent immunosuppressive treatment were associated with higher risk of HP, highlighting the need for focused preventive strategies.

26 June 2026 in Rheumatology International
Verified
Journal Article
Open access
MSMads E. R. Sørensen
Mads E. R. Sørensen
SPSille Sophie Lindhardt Petersen
Sille Sophie Lindhardt Petersen
AOAnne Lund Overgaard
Anne Lund Overgaard
MSMaria Kristina Stilling-Vinther
Maria Kristina Stilling-Vinther
ELEsther Gaarn Lindgreen
Esther Gaarn Lindgreen
SKSalome Kristensen
Salome Kristensen
To investigate the one-year incidence of diabetes mellitus (DM) among patients with giant cell arteritis (GCA) treated with glucocorticoids and interleukin-6 receptor inhibitor (IL-6Ri) compared to patients treated with glucocorticoid monotherapy. Secondary we investigated the one-year risk of a composite outcome of DM, osteoporosis and cardiovascular events. This cohort study at Aalborg University Hospital, Denmark included patients with GCA from June 2022 to August 2025. Data was collected at diagnosis and at 4, 12, and 24 weeks after glucocorticoid initiation, and annually thereafter. We evaluated the one-year incidence of DM, and thereafter the risk the composite outcome using a Cox regression, comparing patients receiving glucocorticoids in combination with IL-6Ri (exposed) versus glucocorticoid monotherapy (unexposed). The study included 121 patients (70.2% female; mean age 70.5 years): 47 exposed and 74 unexposed. A median of 193 days passed from GCA diagnosis to IL-6Ri initiation in exposed. The one-year cumulative incidence of DM was 3.0% in exposed and 17.5% in unexposed. Exposed had a lower composite risk (Hazard ratio: 0.3, 95% confidence interval: 0.1;1.3). The most frequent AEs among exposed were infections, osteoporosis, cardiovascular events, and DM in exposed and unexposed. Both the one-year cumulative incidence of DM and the composite risk of adverse events were lower in exposed compared with unexposed. These findings suggest that IL-6Ri may offer a safer alternative to glucocorticoid monotherapy in reducing long-term risks. Additionally, the data indicate that IL-6Ri may be introduced too late in the disease course.

28 May 2026 in EULAR Rheumatology Open
Verified
Journal Article
Open access
MSMads Engell Refstrup Sørensen
Mads Engell Refstrup Sørensen
KDKirsten Duch
Kirsten Duch
LULine Uhrenholt
Line Uhrenholt
LDLene Wohlfahrt Dreyer
Lene Wohlfahrt Dreyer
JRJohan Røikjer
Johan Røikjer
SKSalome Kristensen
Salome Kristensen

19 June 2025 in EULAR Rheumatology Open
Verified
Journal Article
Open access
FLFie Falk Lauritzen
Fie Falk Lauritzen
BSBolette Gylden Soussi
Bolette Gylden Soussi
KDKirsten Duch
Kirsten Duch
MSMads Engell Refstrup Sørensen
Mads Engell Refstrup Sørensen
AMAnders Sandermann Mortensen
Anders Sandermann Mortensen
SKSalome Kristensen
Salome Kristensen
This study investigated the 5-year all-cause mortality trend for women and men with seropositive versus seronegative rheumatoid arthritis (RA) compared with the background population (BP). Using nationwide registers, a population-based cohort of incident patients with RA diagnosed in Denmark between 2000 and 2014 was identified. Based on immunoglobulin M-rheumatoid factor and/or anticitrullinated peptides, a prespecified algorithm was used to determine the serologic status. The pseudo-observation method was used to determine the cumulative incidence proportion, the age-adjusted risk difference, and the relative risk of mortality. During the study period, the cumulative incidence proportion decreased by at least 50% for both the BP and the RA cohort. The largest change in relative risk was seen for men with seropositive RA compared with seronegative RA, with a relative risk 2000-2004 of 1.1 (95% CI, 0.9-1.4) to a relative risk of 1.4 (95% CI, 1.2-1.7) in 2010-2014. No significant difference was observed for women stratified by serology. Patients with seropositive RA continued to have an excess mortality risk compared with the BP, whereas the relative risk for patients with seronegative RA became similar to the BP. A higher 5-year all-cause mortality risk persisted for patients with seropositive RA compared with the BP. Men with seropositive RA had a higher mortality risk than men with seronegative RA, a difference not seen in women. Future studies are needed to explore the findings of higher mortality risk in seropositive patients and especially the influence of sex and confounders.